While talking with different stakeholders during our project, they often asked us: "What are Human Practices?" Initially, we answered that human practices are interviewing experts on certain topics, and getting their feedback. But as time passed, and many times we had answered this question, we realized that this is not what the true meaning of human practices is. We realized that it is not bombarding academics with questions and awaiting their replies, or asking companies if they would be interested in selling our product, or asking clinicians about how they conduct their clinical practice. It is about listening, about carefully reading between the lines, about looking at the bigger picture. We learned that every person has their unique perspective and story to tell, and it is on us to share it.
Every talk we had was different, with different topics discussed, different opinions, and different questions arising. Each talk was individually assessed, to see how we can implement it into our project, how we can give it a voice, and how we can contribute to bridging the gaps mentioned. Even though every talk was different, most of them agreed on one thing: there is not enough research on PMOS.
I love when you do research on PMOS because honestly, there really isn't enough.
Our conversations fell into three groups, which we treat as the pillars of our human practices work:
Stakeholders
For a project to move beyond a proof-of-conceptA first test showing that an idea can work, before it is developed into something usable., it has to consider, and be considered by, people outside of the laboratory. A therapeutic can reach a patient only if it can be developed, manufactured, classified, prescribed, afforded and trusted. Each of those steps belongs to a different group of people with its own priorities and reasons to say no to it. Throughout the project, we have tried to reach most of these groups, and treat them as participants in the design by implementing their feedback, rather than treating them as obstacles.
By mapping the path our product would have to travel from a construct in the lab to a therapeutic in the clinic, we have identified five groups of stakeholders. They do not form a list, but rather an interdependent cycle: academics develop, industry produces, regulators establish safety, clinicians prescribe, and patients give their feedback, redirecting the research and development. Each group affects the one after it, and the last one closes the cycle back to the first.
Select a slice to read about it.
People living with PMOS
People living with PMOS taking therapy understand better than anyone what taking it is actually like. That experience would return to researchers and academics, who would implement their feedback, in the hope of improving the therapy even more.
Academia
Researchers and the synthetic biology community design, build, and test the therapy. However, this does not happen in isolation: what clinicians, regulators and patients need from a therapy shapes how it's built in the first place.
Industry
Industry produces the therapeutic at a large scale. Every batch has to meet the same quality standards, so that what a patient receives is consistent and predictable. This also constrains what can be designed. A therapy that cannot be produced consistently, or at a cost that allows it to reach people, will not become a treatment regardless of how it works in the laboratory.
Regulators
Regulators and biosafety authorities decide what a product legally is, and whether its benefits justify its risks. Nothing reaches the clinic without their approval. What is not permitted, and what must be demonstrated, shapes how the therapeutic is built.
Clinicians
Clinicians decide whether a therapy reaches a patient. They weigh it against the options already available and identify who it is unsuitable for. They also see how a therapy performs in a real population, which side effects matter, and whether people keep taking it. All of that can be used as feedback into how the therapy is developed.
Integrated HP
Throughout the development of the project, we consulted researchers and experts across different fields to evaluate our assumptions and shape our decisions. We spoke with specialists in steroid-transforming enzymes, PMOS and hyperandrogenismHigher than normal levels or effects of androgens, the male sex hormones such as testosterone. research, microbiome containment, sustainability practice, clinical practice, and innovation management, just to name a few.
Each conversation is summarized below, together with what we learned and how it shaped the project.
Academia
Anna Benrick
Professor in Endocrinology
Department of Physiology, University of Gothenburg
Anna Benrick's research focuses on hyperandrogenism and its link to reproductive diseases in females. She was contacted to help us with understanding more about PMOS, hyperandrogenism and the feasibility of our approach. Dr. Benrick confirmed 5β-reductase-targeted androgen reduction is a valid therapeutic approach, and advised us against an androgen-inducible expression strategy, favoring stable overexpressionMaking the cells produce a lot of the enzyme all the time, rather than only when a signal switches it on. instead.
Summary of interview:
We consulted Dr. Anna Benrick, whose research focuses on the molecular link between androgen excess and the development of reproductive disorders, obesity, and type 2 diabetesA long-term condition in which the body cannot use insulin properly, so blood sugar stays too high. in women. The interview was centered on the feasibility of the AnTigone project, whether locally reducing testosterone in the gut could meaningfully affect systemic testosterone levels and reduce hyperandrogenism symptoms. Despite promising preclinical findingsResults from laboratory and animal studies, before any trial in people., Dr. Benrick emphasized that the gut microbiotaThe community of microbes living in the gut.-PMOS field is still young, and it remains unclear whether microbiota changes drive PMOS or result from it.
A recurring topic in the interview was the uncertainty about gut-to-serum steroid circulation: how much testosterone actually passes through the gut relative to what is produced by ovaries and adrenal glands. This uncertainty was raised to answer one of our main questions, whether our approach could achieve a biologically relevant effect. We had discussed the possibility of incorporating a testosterone-sensing mechanism to induce enzyme expression and deactivate it if reduction became too high. She advised not to pursue this, but to prioritize stable, strong enzyme expression, since insufficient effect was deemed more likely to happen than excessive androgen lowering. Furthermore, she did not anticipate a compensatory increase in androgen production in response to our treatment.
The conversation also touched on validation strategy, including in vitro options such as testosterone-producing theca cellsCells in the ovary that make androgens., and candidate biomarkersA measurable substance that signals what is going on in the body. such as testosterone, androstenedioneA hormone made in the ovaries and adrenal glands that the body can convert into testosterone. and hydroxyandrogens, alongside clinical symptoms such as menstruation frequency or body hair. Dr. Benrick raised the possibility that a gut-localized, low-risk approach could be relevant for PMOS treatment during pregnancy, a period in which most hormonal therapies are avoided due to their possibility of affecting fetal development.
Project framing - framing the project as an early-stage hypothesis rather than a validated therapeutic mechanism
Figure 1. Picture from a meeting with Anna Benrick.
Helena Berglund
Assistant Head of Teacher Education
Joint Faculties of Humanities and Theology, Lund University
Helena Berglund is Assistant Head of Teacher Education at Lund University's Joint Faculties of Humanities and Theology, with a research focus on how teacher professionalism can be strengthened through the right conditions in schools and teacher education. Given her expertise, she has insight into how the Swedish school system works and what makes outreach material well-suited for students. We contacted her early on for feedback and support on our high school outreach package, to understand which approaches could realistically create the highest impact. She confirmed our target age (15–18, pre- and post-specialization), pushed us toward hands-on/practical formats over plain lectures, made us consider school segregation, and confirmed language wouldn't be a barrier, given students' English proficiency.
Summary of interview:
Given her research background in teacher professional development, Helena Berglund was contacted to get early feedback on our high school outreach concept and to identify the approaches with the highest impact.
The main topics discussed were: ideal target age, format, the structure of the Swedish school system, the relevance of school segregation, and language requirements. Helena confirmed 15/16 to 18 (pre-specialization and post-specialization = from 9th year onward) as the ideal target age.
She recommended hands-on laboratory work and workshops over lectures alone, as these have a high learning and retention effect on students. She also noted that teachers are generally looking for activities that are easy to fit into an already busy curriculum. She explained the segregation between municipal schools and non-municipal, often profit-driven schools (friskolorSwedish independent schools, often run for profit.) as a reason for unequal access to practical activities, pointing us to SkolinspektionenThe Swedish Schools Inspectorate. for insight into school quality data and suggesting we could prioritize socioeconomically weaker areas as high-impact targets. She confirmed English-language material is fine given students' strong proficiency. She also highlighted linking science to its societal relevance as the most engaging angle for student interest.
Language - Her reassurance that English is widely understood by Swedish students let us proceed with the high school package in English, which was necessary at the time since we had no Swedish-speaking team member.
Content framing - Her advice to link science to its societal relevance reinforced the approach we started with, using iGEM to show the range of experts involved in synthetic biology (ethics, policymakers, researchers, etc.).
Eduardo Amo González
Doctoral student in Computational Biology
Center for Molecular Protein Science, Lund University
Eduardo Amo González is a doctoral student at Lund University, and was a Dry Lab Leader of last year's iGEM Lund Team. He was contacted for advice on how to approach protein and mutation modeling during the early stages of the project, and on which software programs he would recommend. He suggested using ChimeraXA program for visualizing and analyzing 3D molecular structures., as it is user-friendly and suited for beginners. He also introduced us to iGEM at the very beginning of the project and explained what the competition involves.
Integration:
Modeling Software - Based on Eduardo's advice, we decided to use ChimeraX for protein visualization and mutation modeling.
Tsz Yan Clement Chan
Associate Professor in Bioengineering
Department of Biomedical Engineering, University of North Texas
Dr. Clement Chan is an expert in genetic circuits which can be used for biocontainment. He was contacted to get insight into the possible biocontainment strategies for our product. Based on his feedback, we decided to focus our experimental work on in vitro proof-of-concept only, but discuss the biocontainment theory thoroughly, postponing its practical implementation to future work. We also had to consider our choice of future probiotic chassisThe host organism that carries the engineered genes. based on where testosterone is actually reabsorbed in the gut.
Summary of interview:
We contacted Dr. Chan because of his expertise in genetic circuits and biocontainment systems. We wanted his perspective on what biosafety measures we should implement.
Dr. Chan outlined two main approaches for biocontainment strategies: non-canonical amino acid incorporationMaking an organism depend on an artificial amino acid that does not exist in nature. and kill-switchesA genetic circuit that kills the bacterium under defined conditions., and pros and cons of each. Dr. Chan informed us that modern biocontainment is multi-layered, and uses 3-4 different mechanisms simultaneously, since no single mechanism is sufficient. We also discussed his novel kill-switch design, a CRISPRA gene-editing system that cuts DNA at a sequence chosen with a guide RNA.-based genetic circuit, that instead of killing bacteria, uses CRISPR to destroy only the engineered genes. This method could be preferable to traditional kill-switches, since he said that toxin-based killing is difficult to maintain efficiently in gastrointestinal systems.
He also shared his experience as an iGEM judge, and gave advice on the feasibility of our gut-based approach, and the appropriate experimental scope for iGEM. He also advised that chassis selection depends critically on where testosterone is reabsorbed (small intestine favors Lactobacillus sp., while colon favors E. coli Nissle 1917).
Most importantly, Dr. Chan recommended focusing exclusively on demonstrating the metabolic pathway works in vitro, as biocontainment alone could be an entire iGEM project. While the hypoxia gate that we implemented could be considered a biosafety layer, since it limits environmental spread, it is not sufficient alone. Thus proper biosafety implementation for our product is something that future iGEM teams can build on.
Integration:
Chassis validation - we had to determine primary testosterone reabsorption site (small intestine vs. colon) before finalizing end chassis choice (E. coli Nissle 1917 or Lactobacillus sp.).
Biocontainment - we removed biocontainment from planned experimental work and repositioned it as "future implementation" discussion only.
Figure 2. Picture from a meeting with Tsz Yan Clement Chan.
Eleni Dubé Zinatelli
PhD candidate in Experimental Psychology
University of Ottawa
Eleni Dubé Zinatelli's doctoral research focuses on the impact of PMOS on mental health. She was contacted to discuss the mental health burden of PMOS and how specific symptoms could correlate with psychological distress. She noted how reducing hyperandrogenism symptoms such as hirsutismExcess dark, coarse hair growth in a male-like pattern, e.g. on the face, chest or back. or acne could have a positive impact on the mental health of women with hyperandrogenism. She emphasized that PMOS still remains an under-researched area.
Summary of interview:
Eleni Dubé Zinatelli is a PhD candidate, whose research focuses on the impact of PMOS on mental health, with an emphasis on women's health and how reproductive hormones influence brain function. We reached out to her to get her point of view on PMOS-related mental health outcomes and her feedback on the project.
Eleni agreed that reducing testosterone in a context of a therapeutic like ours could meaningfully help the physical symptoms of hyperandrogenism such as hirsutism, acne and alopeciaHair loss or thinning.. She stressed how the body image tied to these symptoms is one of the central burdens in women with PMOS. She noted how this disorder is multifaceted and cannot be addressed with a single intervention. However, improving even one of the previously mentioned symptoms could meaningfully help patients, not only in mental health but also body image and identity.
She was positive about the project's framing. Since PMOS is increasingly understood as a polyendocrine, metabolic condition rather than a purely hormonal one, she saw value in an approach that isn't a hormonal treatment or an insulin sensitizing approach, describing our project as a ‘different lens' the field needs. She emphasized the gut-microbiome angle as underexplored in PMOS research, mentioning it should be investigated further.
Eleni raised a concern regarding PMOS phenotype DOne of the four PMOS phenotypes: irregular ovulation and polycystic ovaries, but no excess androgens. (the non-hyperandrogenic phenotype). Patients with this phenotype are often dismissed by doctors because they lack the more visible hyperandrogenic symptoms. This leaves many women undiagnosed and unsupported for years while they continue searching for answers. She identified this as a systemic diagnostic gap, not something our therapeutic addresses, but a gap in the current system that deserves more attention, helping women with less visible hyperandrogenic symptoms get recognized and diagnosed sooner.
She noted multiple times that PMOS remains significantly under-researched, and welcomed the increasing attention to it from student research teams.
Integration:
Raising awareness - Eleni's comments on phenotype D shaped our decision to include it in the PMOS Awareness Month activities, where we aimed to raise awareness of that diagnostic gap.
Gut-localized approach - By pointing to fecal-microbiota transplantTransferring stool from a healthy donor into a patient's gut to change their gut microbes. studies, Eleni strengthened the rationale in our project, for why a gut-localized therapeutic is a reasonable approach to pursue.
Trevor M. Penning
Professor in Pharmacology
Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania Perelman School of Medicine
Trevor M. Penning is an expert in steroid-transforming aldo-keto reductases, including AKR1D1. He was consulted to assess the use of AKR1D1 in our approach, and to discuss potential limitations. He confirmed the enzyme converts testosterone to 5β-DHT5β-dihydrotestosterone, the less active form of testosterone after 5β-reduction. quite well, affirming our effectorThe part of the system that carries out the intended action, here the enzyme that transforms the steroid. choice. He noted that AKR1D1’s broad substrate affinity could present an issue and that multiple point mutationsChanges to single amino acids in a protein, made by altering one letter of its gene. across the binding pocket would be needed to overcome this challenge, which could pose difficulties within our limited timeline.
While discussing issues with substrate specificity, Dr. Penning explained how any substrate with Δ4-3-ketosteroid structure in the steroid ring is a plausible 5β-reduction substrate, which is a primary reason single-steroid specificity is hard to engineer on Δ4-3-ketosteroid reductases. To achieve single steroid specificity, engineering would require multiple point mutations across the substrate pocket. Dr. Penning cautioned us how that would be an extremely difficult task, considering our limited time for the project.
We contacted Ana Nordberg, to better understand EU and Swedish laws regarding data protection and patents relevant to our project. We further discussed GDPR and consent requirements while collecting patient data, ethical conduct while interviewing a patient and filing patient information.
While using anonymous data, she explained it doesn't need the same permissions, but still has to follow GDPR regulations and must be secured properly, so that the data does not get re-identified. She also mentioned that consent requirements depend on the type of data collection: written consent is needed for clinical trials, but for something like a survey, consent can be built into the survey itself, as long as participants are properly informed beforehand. One thing she did highlight was that once someone consents, they can't retroactively pull their data if it's already been used in aggregate analysis, that is if we want to reuse data later, we should generate anonymized versions early, so a withdrawal doesn't disturb the dataset.
If we do talk to patients, she was clear that it can't just be a casual conversation and always has to follow data protection rules. That means thinking through how questions are phrased, having a plan to stop an interview if someone gets upset or uncomfortable, and masking voices if we record anything. Anything with human subjects should also go through the course's ethics board first.
She sent us the relevant regulations afterwards that set a great starting point for developing the GDPR part of the surveys.
Integration:
Survey Structure - Her input served as a starting point for developing the GDPR regulations and ensuring proper consent for the clinician and patient surveys. The latter was not published due to lack of time to get the ethical review for it.
Regulatory Research - Looked further into GMO regulations based on her input on our product's classification.
Elisabet Stener-Victorin
Professor of Reproductive Physiology
Karolinska Institutet
Elisabet Stener-Victorin is an expert in PMOS, reproductive endocrinology, hyperandrogenism, and metabolic dysfunction, whose research closely aligns with our project. We contacted her to evaluate the clinical relevance of targeting androgen activity through the gut and to better understand which aspects of hyperandrogenism are most important in PMOS. Her insights led us to realize our reduction target is free testosterone, rather than SHBGSex hormone-binding globulin, a blood protein that holds sex hormones in an inactive, bound form.-bound one, along with framing AKR1D1 as a proof of concept rather than a definitive therapeutic target.
Summary of interview:
Elisabet Stener-Victorin specializes in PMOS, reproductive endocrinology, hyperandrogenism, and metabolic dysfunction. We contacted her because her expertise is highly relevant to our project, particularly to evaluate whether targeting gut-derived androgen activity could be a clinically meaningful approach for PMOS.
We discussed whether reducing androgen activity in the gut could meaningfully affect systemic androgen levels and PMOS symptoms, and whether AKR1D1-mediated 5β-reduction is a suitable approach. We also asked which androgens and biomarkers are most clinically relevant, whether excessive androgen reduction could pose risks, and whether a gut-based approach could offer advantages for women seeking pregnancy. Finally, we discussed the relationship between hyperandrogenism, metabolic dysfunction, and inflammation in PMOS.
She agreed that hyperandrogenism is a relevant target, and emphasized that the measure which matters is free testosterone, the bioactive fraction, rather than total testosterone, most of which is bound to SHBG and not bioavailable. She considered AKR1D1 useful as a proof of concept but noted that its direct relevance to PMOS remains uncertain and that other androgen pathways may ultimately be more suitable targets. Lowering circulating androgens could potentially improve hormonal feedback, although this remains hypothetical, and androgen levels should be normalized rather than reduced excessively. Importantly, she highlighted the potential value of a gut-based approach for women seeking pregnancy, since several current anti-androgen treatments cannot be used during this period. She also suggested that inflammation in PMOS may largely be secondary to hyperandrogenism, hyperinsulinemiaToo much insulin in the blood., and metabolic dysfunction.
Figure 3. Picture from a meeting with Elisabet Stener-Victorin.
Suman Rice
Reader in Reproductive Physiology
School of Health and Medical Sciences, University of London
Suman Rice is a reproductive physiologist specializing in women's reproductive health, so we contacted her to better understand the hormonal complexity of PMOS and evaluate our androgen-targeting approach. She emphasized that PMOS is highly complex and that treatment needs to differ depending on symptoms, age, and life stage. Based on her feedback, we decided to define our target patient group and treatment goal more clearly, while paying greater attention to the safety and limitations of androgen reduction.
Summary of interview:
We contacted Suman Rice because of her expertise in reproductive physiology and women's reproductive health. We wanted her perspective on whether reducing androgen activity could be a reasonable therapeutic approach for PMOS and what physiological factors we should consider.
We discussed androgen production and regulation in PMOS, the roles of testosterone and aromataseAn enzyme that converts testosterone into estrogen., and limitations of current treatments such as antiandrogen pills and metforminA drug that improves the body's response to insulin, also used off-label in PMOS.. We also discussed our gut-based approach, suitable target populations, and potential safety concerns.
She emphasized that PMOS involves multiple interconnected hormonal and metabolic pathways, so targeting testosterone alone may not address the whole condition. She also advised us to clearly define which patient group and symptoms we aim to target, and highlighted the importance of considering systemic effects and pregnancy safety when developing an androgen-reducing treatment.
Integration:
Gut mechanism - We reconsidered how gut-localized treatment could affect systemic androgen levels.
Figure 4. Picture from a meeting with Suman Rice.
Christina Wennerberg
Project Assistant
Division of Biotechnology and Applied Microbiology, Lund University
Christina is a project assistant who actively implements sustainability practices in student labs at LTH (Lund University), so we wanted her opinion on our current lab practices and her input on what to focus on for a potential student lecture on lab sustainability.
The main topics discussed were the current state of sustainability teaching in labs (courses mostly cover it from an industrial angle, general safety regulations may also touch on it, and how sustainable a lab is depends heavily on lab type); concrete sustainability practices (glassware reuse, using experiments to identify reusable/recyclable material, contacting suppliers for greener chemicals); and our idea for a "Sustainability in the LabSustainability in the Lab: Internal Workshop1 June 2026, Kemicentrum, Lund
For: iGEM Lund wet lab team (9 people)Go to page: Education" lecture: who to target, how to frame it, whether to include chemical comparisons, and which equipment to highlight.
Christina gave overall positive feedback on the lecture idea. She suggested targeting the mandatory course within each Swedish specialization track, and extending the same offer to international master's students across specializations (pharma, food, biotech). She recommended framing the lecture around building sustainable habits over time, using quantitative, visual examples of how waste accumulates at scale to make the impact tangible. She raised the idea of comparing green vs. traditional chemicals. She also suggested focusing on the most energy-intensive lab equipment, such as freezers. On her own practices, she noted these were informal habits rather than a documented standard, and suggested looking online for something more rigorous. She agreed to give us feedback on the finished lecture and help advertise it to students.
Framing - We built the lecture around forming sustainable habits, using quantitative, visual examples of waste accumulation to make the impact concrete rather than abstract.
Chemical comparisons - We included green chemistryDesigning chemical processes to reduce waste and hazardous substances. as a topic in the lecture.
Equipment focus - We prioritized the most energy-intensive lab equipment, such as freezers, as a lecture focus point.
Practical tips - We incorporated her concrete practices (glassware reuse and using experiments as a chance to identify reusable/recyclable material) as practical takeaways in the lecture.
Review & promotion - She reviewed our finished lecture, offering valuable feedback, and helped advertise it.
Johan Tejler
Work Environment Coordinator
Lund University
Johan Tejler is the work environment coordinator at the Department of Chemistry at Lund University. He coordinates the work safety regarding chemicals, waste and water management at Kemicentrum (KC), where our lab was located. We contacted him because he has an overview of the regulations that need to be adhered to, as well as of ongoing projects regarding safety and sustainability in KC. We discussed with him our ideas for improving sustainability in the laboratory we were working in and came to realize that KC has already implemented many sustainable practices.
Summary of interview:
Johan is the work environment coordinator at the Department of Chemistry at Lund University. Since he has an overview of regulations and ongoing projects we wanted his insights on the issue of sustainability in the lab. We learned about the different competences at KC regarding water, waste and electricity management. Since KC is rented and there are multiple departments located within KC, some of these fall under different authorities, making it a lengthy process to make sustainable changes that involve multiple players. From our research we had some ideas on what we could implement in order to make our laboratory work more sustainable, which we were able to discuss with Johan. During our conversation we came to the conclusion that most of what we had in mind (reducing water pressure, using timer plugs, avoiding hazardous chemicals) was already implemented within KC. Finally, we discussed the impact and feasibility of sustainability in the lab compared to those of sustainable life choices (e.g. biking, taking public transport).
Nelida Leiva Eriksson
Associate Professor in Molecular Biotechnology
Division of Applied Microbiology and Microbiology, Lund University
Nelida Leiva Eriksson is an Associate Professor and Senior Lecturer, with a field of research in biochemistry, molecular biology and synthetic biology. Considering she was a PI for iGEM teams in the past, she was contacted for insight on how to organize the technical development at project start. To minimize the risk of not finishing our project, she suggested prioritizing a better characterized 5β-reductase, such as AKR1D1. If we wanted to express both AKR1D1 and ci2350, she advised us to parallelize their expression in order to make the lab work more time-efficient. She stressed the importance of teamwork and out-of-office activities in strengthening the team bond.
Integration:
Parallelizing expression - Based on her advice, we parallelized the expression of AKR1D1 and ci2350, in order to make the wet lab work more time-efficient.
Group activities - We implemented a board game night most Sundays, to strengthen the team bonding and unwind.
Savvina Leontakianakou (not finished)
Doctoral student in Enzyme Technology, former iGEM judge
Division of Biotechnology and Applied Microbiology, Lund University
Savvina Leontakianakou is a doctoral student in enzyme technology. She was a member of the 2019 iGEM Lund team that won a gold medal and has since served as an iGEM judge. We contacted her to troubleshoot our NADPHA molecule that carries electrons for enzymes. Its level can be followed by light absorbance to measure enzyme activity.-based enzyme assay, after our empty-vectorA control carrying the plasmid without our gene. control showed activity (assay development), and to ask how to structure the Design-Build-Test-Learn (DBTLDesign-Build-Test-Learn: the engineering cycle iGEM teams use.) cycle on the wiki. She advised us on handling the background activity, setting up the controls and keeping the DBTL cycles connected.
Summary of interview:
We contacted Savvina because our assay showed a clear absorbance shift in the control with empty pET-11aA common plasmid for producing proteins in E. coli. controls, which suggested that native E. coli proteins in the purified fraction react with NADPH. We also wanted her advice on a nested DBTL structure, on mass spectrometryA technique that identifies and measures molecules by their mass., and on whether to do ELISAEnzyme-linked immunosorbent assay: an antibody-based test that detects and measures a specific molecule. assays.
By email, she asked how the control is purified and advised us to run SDS-PAGE on it and compare it with the gel of the purified target, to measure protein concentration, and to subtract the background activity from the measured activity. She suggested size exclusion chromatographySeparating molecules by size as they pass through a column of porous beads. for further purification and mass spectrometry through a colleague at Kemicentrum, and advised us to establish our current assay before pursuing an ELISA assay. For the DBTL cycles, she said that smaller nested cycles are fine as long as a thread connects them.
In a later in-person meeting, she gave more advice: include negative controlsSamples where no result is expected, used to rule out false positives. with and without IPTGA lab chemical that switches on genes controlled by certain promoters. for the construct without the enzyme, run assays soon after purification because stored enzyme loses stability, and check the VivaspinA brand of spin filters that concentrate protein samples by spinning them through a membrane. flow-through to see what we lose.
Background subtraction - negative control's activity was supposed and suggested to be used as the baseline, in order to be able to report only the activity above it. Unfortunately our results didn't allow to integrate the suggestion.
Scope - given the very limited time left, we decided to finish and understand the current assay instead of adding the Testosterone ELISA Kit or the Thermo Fisher Human Androgen Receptor Kit. We also did not run mass spectrometry, because there was no time to organize access across divisions.
DBTL structure - we used several smaller DBTL cycles and kept a common thread running through them.
Postdoctoral Fellow in the lab of Dr. Martin Blaser
Center for Advanced Biotechnology and Medicine, Rutgers University
Liisa Veerus is a Postdoctoral Fellow researching interdependence between the microbiome and health. She was contacted via email for her perspective on the mechanistic direction of the project. She confirmed that the 5β-reduction strategy is a reasonable and experimentally tractable starting point, noting that direct androgen biotransformation provides clear, measurable outputs in vitro, and that a reductionist approach is the right way to begin.
Integration:
Effector choice - Liisa's feedback that the 5β-reduction strategy is a valid starting point reinforced our choice to use it for our proof-of-concept.
Juan Pablo del Río
Specialist in Child and Adolescent Psychiatry
Department of Child and Adolescent Psychiatry and Mental Health, University of Chile
Dr. Juan Pablo del Río researches how prenatal and adolescent hyperandrogenism affects brain development and neuropsychiatric outcomes, including the "dual-hit hypothesisThe idea that an early exposure makes the brain vulnerable and a later second stressor then triggers disease." linking early androgen exposure to later mental health risk. He was contacted to understand how a gut-localized, androgen-lowering therapeutic like ours might intersect with the neuropsychiatric burdens seen in PMOS. His insight gave us a new perspective on whether gut testosterone reduction could plausibly extend to systemic or brain-level effects.
Summary of interview:
We primarily contacted Dr. del Río to understand how targeting gut testosterone might cause neurodevelopmental and mental-health-related issues with PMOS. We also wanted to ask him which part of the dual hit hypothesis is most actionable for early intervention. We also discussed which neurodevelopmental pathways are most sensitive to hyperandrogenism and how to discuss PMOS and neurodevelopment without stigmatizing language.
He explained that pinpointing the specific androgen responsible for PMOS pathology is difficult, since testosterone is often used as a proxy due to ease of measurement, but hyperandrogenism isn't driven by testosterone alone. Testosterone can convert into estrogen and progesterone, and other androgenic metabolites likely contribute, so any therapeutic targeting testosterone specifically should account for these broader steroid interconversions.
On neurodevelopment, he described growing evidence that prenatal androgen exposure affects microglialThe immune cells of the brain. activity, pushing microglia toward a more inflammatory phenotype that can affect the prefrontal cortexThe front part of the brain involved in planning and decision-making. and memory/social recognition circuits which could possibly be a synergistic effect involving hormonal, inflammatory, and metabolic factors together, not testosterone alone. He also referenced functional MRIBrain scans that show which areas are active by tracking blood flow. research showing reduced prefrontal cortex–amygdalaA brain region involved in processing emotions such as fear. connectivity in women with PMOS, which may underlie increased anxiety and depression, and suggested we follow up with the researcher behind that study.
On therapeutic implications, he noted there's currently limited direct evidence linking androgen reduction to improved mental health outcomes, and highlighted a bidirectional relationship between hyperandrogenism and insulin resistanceThe body's cells respond poorly to insulin, so more insulin is needed to keep blood sugar in range. that makes it hard to isolate the effect of androgen reduction specifically. On our project, he raised open questions about whether reducing gut testosterone could produce unintended endocrine effects, how much systemic androgen levels would actually be affected by a gut-localized approach, and whether inducible expression would offer more safety and control than constitutive secretion.
Integration:
Communication/Awareness building - Being careful not to overstate mental health benefits given the limited direct evidence linking androgen reduction to psychiatric outcomes.
Martin Hedström
Senior lecturer in Bioanalytical Chemistry
Division of Biotechnology and Applied Microbiology, Lund University
Martin Hedström is a bioanalytical chemist, with main fields of work in mass spectrometry, immunoanalysis and biosensors. He was contacted for advice on how to approach detecting and quantifying steroids in our experimental work. While we initially opted to use mass spectrometry for steroid detection, Martin suggested looking into the possibility of using an enzymatic assay for leftover testosterone from our testosterone reduction assays, given the cost and complexity of mass spectrometry equipment.
Mahnaz Bahri-Khomami
Adjunct Senior Research Fellow in Women's Health
Monash Center for Health Research and Implementation, Monash University
Dr. Mahnaz Bahri-Khomami was a lead researcher on the international PMOS guideline development and name-change consensus process. We contacted her to gain more insight into unmet clinical needs, research gaps, and patient priorities in PMOS. Given the time difference between Sweden and Australia, she agreed to a written interview. She answered our questions within her area of expertise which covers clinical need, patient priorities, safety, and terminology, and connected us with further experts for our biochemical and microbiome-related questions.
Summary of the interview:
We contacted Dr. Bahri-Khomami to get a professional perspective on unmet needs, research gaps, need for a name change and future directions relevant to our project. Due to a wide time difference and previous commitments, she agreed to do a written interview with us. We covered a wide range of topics: whether our gut-targeted mechanism addresses a meaningful clinical need, which patient subgroups benefit the most, the minimum safety evidence required before advancing toward animal or clinical development, reproductive and pregnancy safety and finally correct use of PMOS terminology.
On the mechanism, she wrote that the real question is not whether the intestinal androgen bioactivity can be reduced but whether it can be reduced enough for it to matter, which helped us to start thinking about clinical meaningfulness and cost-effectiveness threshold quite early. She also highlighted that patients with type 2 diabetes will most likely benefit from this and encouraged us to see our platform as a multidirectional strategy rather than a standalone replacement.
On safety, she said human studies are always done after animal studies. She also mentioned that since the therapy targets a population of reproductive age several reproductive safety questions need to be resolved before moving forward: whether it or any of the byproducts cross the placenta, how the product might affect male fetal development and what contraception or washout periodThe time needed for a drug to clear from the body before the next treatment or test. would be required during the use of the probiotic.
On our questions regarding accessibility she mentioned manufacturing costs, clinician education and reimbursementsPayment of a medicine's cost by a health system or insurer. as key barriers making this therapy more inaccessible to those who really need it.
She also wrote that in her years of research she has observed patients' reluctance towards systemic hormonal treatment over the years. She highlighted that this reflected a desire to address the underlying condition without a systemic route, and described the issue as pill burdenThe inconvenience of taking many tablets every day..
Target subgroup - Exploring patients with PMOS and insulin resistance or type 2 diabetes as a possible target group, since they are likely to benefit most.
Design priority - Prioritizing whether the therapy replaces existing treatment rather than adding to it, since patients weigh new products against how much they simplify (or complicate) their existing routine.
Terminology - Using "PMOS instead of PCOS" at first mention throughout project materials.
Nelly Garcia Gonzalez
Associate Senior Lecturer in Materials Engineering
Division of Environmental and Energy System Studies, Lund University
Nelly Garcia Gonzalez is an Associate Senior Lecturer in the Division of Environmental and Energy Systems Studies at Lund University. Her work centers on bio-based materials and sustainability and she has extensively worked on making Life Cycle Assessments (LCA)A method for measuring the total environmental impact of a product from raw materials to disposal.. We reached out to her for her expertise in LCA, aiming to decide if performing an LCA for our project was possible.
Summary of interview:
We contacted Nelly Garcia Gonzalez, since sustainability is a main part of our project, and we wanted an expert's view on whether we could carry out an LCA ourselves.
The main points discussed were what an LCA involves, from structuring data to quantifying every input and output; what information our lab work would need to provide; and how to limit the scope given our limited time and resources.
She highlighted that data collection is the most crucial step. We would need precise, detailed information on the materials and methods used in the lab, the energy used and the quantities, with each method broken down into individual steps. These data would then go into LCA software to create an initial assessment. Also, a traditional LCA covers 14 impact categories. With limited time and resources, we could focus only on the materials used, with greenhouse gas estimation as one possible focus.
Integration:
Decision on LCA - we decided not to perform an LCA. Her explanation of the data needed made us see that, with our time constraints and limited experience, we could not produce a well-rounded assessment.
Scope - her advice to narrow the scope (materials only, or greenhouse gases) helped us judge how much time and effort an assessment would take.
Future option - her guidance gives a starting point if a later team wants to carry out an LCA.
iGEM Munich 2025
Winning team of Best Wiki award in the iGEM 2025 Competition
Anna Tichá, Jonas Turzanski Fortner and Giuseppe Oricchio
The 2025 iGEM Munich team won Best Wiki, among other awards. To make our wiki the best representation of our project, we contacted team members to learn what they thought contributed to the win. In a call, we spoke with Anna Tichá (lead designer of the wiki), Jonas Turzanski Fortner (lead coder of the wiki) and Giuseppe Oricchio (project manager). Following their advice, we set up a system that lets everyone on our team write directly to the wiki, adjusted our design elements to improve accessibility, and added navigation and glossary components to make the wiki easier to move around in. When we asked about fancy graphics and complex animations, their advice was “less is more”, so we focused on usability and readability.
Clinicians
Lina Zabulienė
Endocrinologist with expertise in PMOS
Vilnius University
Dr. Lina Zabulienė is an endocrinologist with extensive clinical and research experience in PMOS. We contacted her to discuss the target patients and safety of our gut-based therapy. Her feedback highlighted the need to avoid excessive androgen reduction and strengthened our focus on gut-specific expression, and a kill switch for bacterial containment.
Summary of interview:
Dr. Lina Zabulienė is an endocrinologist with extensive clinical and research experience in PMOS. We reached out to her for her clinical perspective on our target population, the effects of reducing androgen levels, and the safety considerations of using an engineered probiotic. When discussing who could benefit from our therapy, she highlighted women who experience intolerance to current treatments such as oral contraceptives or metformin, as well as those with contraindicationsConditions or situations in which a treatment should not be used. to contraceptives. She also suggested that our approach could be relevant for women planning to conceive, who cannot use certain anti-androgenic treatments. However, she advised against using a live bacterial therapeutic during pregnancy.
She supported lowering testosterone as a therapeutic approach, explaining that reducing elevated testosterone could improve not only hyperandrogenic symptoms but potentially also folliculogenesisThe maturation of follicles, the small sacs in the ovary that each hold a developing egg. and irregular ovulation. However, she emphasized that testosterone should not be reduced excessively, as low androgen levels can affect libido, muscle strength and bone health. From her clinical experience, a reduction of around 30% can already improve symptoms, making controlled rather than maximal androgen reduction important for our therapeutic.
Regarding our 5β-reduction strategy, she highlighted the importance of enzyme specificity. Since 5β-reductase can act on other steroids, including progesterone and cortisol, she encouraged us to ensure that our enzyme preferentially targets testosterone to minimize unwanted effects on other steroid hormones.
Finally, she identified systemic hypoandrogenismAbnormally low androgen levels. and bacterial translocationBacteria crossing the gut wall into the body. across the intestinal barrier as two important safety concerns. To improve bacterial containment, she supported chromosomal integration rather than plasmids, gut-specific expression, and a kill switch to prevent the engineered bacteria from surviving and spreading outside their intended environment.
Integration:
Target population - Her feedback led us to focus on patients with intolerance or contraindications to current treatments, while considering preconception rather than pregnancy as a potential use case.
Controlled reduction - We shifted our goal from maximizing androgen reduction to achieving a controlled reduction, minimizing the risk of hypoandrogenism.
Enzyme specificity - Her concerns about effects on progesterone and cortisol strengthened our focus on engineering the enzyme toward preferential testosterone conversion.
Bacterial containment - Her safety concerns reinforced our two-layer containment strategy: gut-specific expression, and a kill switch.
Figure 5. Picture from a meeting with Lina Zabulienė.
Angelica Lindén Hirschberg
Professor of Obstetrics and Gynecology and Senior Consultant in Gynecological Endocrinology
Karolinska Institutet
Angelica Lindén Hirschberg is a Senior Consultant and Professor, whose research focuses on disorders of reproductive function and gonadal development in women. We reached out to receive her clinical perspective on our project and its feasibility. She confirmed that targeting testosterone is a sound first step, and that the gut-localized approach is plausible, given known enterohepatic recirculationSubstances released from the liver into the gut via bile are reabsorbed and carried back to the liver, instead of leaving the body. of androgens.
Summary of interview:
Angelica Lindén Hirschberg is a Professor of Obstetrics and Gynecology at Department of Women's and Children's Health, Karolinska Institutet and Senior Consultant at the Department of Gynecology and Reproductive Medicine, Karolinska University Hospital. Her research's aim is to improve diagnostics, fertility and long-term health in women with disorders of reproductive function and gonadal development. We reached out to her for her clinical perspective on the project, its mechanism and feasibility.
When discussing whether targeting testosterone would be a reasonable first step, she confirmed it without hesitation. She also confirmed the premise of our gut-localized approach is sound, due to a major route of androgen elimination being via the gut, though she could not provide exact figures on what amount.
If our therapeutic manages to lower testosterone levels in women, she does not expect a systemic compensatory reaction such as a negative feedback loop, noting how this feedback regulation is male-specific and does not apply the same way in women. She agreed that lowering testosterone could improve ovulation frequency in women with irregular ovulation, suggesting the therapeutic's relevance could extend beyond lowering hyperandrogenic symptoms.
Since combined oral contraceptives already effectively reduce testosterone levels, she suggested our therapy would be appreciated with women who cannot or choose not to take combined oral contraceptives, rather than a universal replacement. When asked which group would be excluded from our gut-localized therapy, she identified patients with gastrointestinal diseases as the most obvious ones, as they could have contraindications.
She defined PMOS as a mild form of hyperandrogenism compared to more severe causes like ovarian hyperthecosisA rare condition in which ovarian tissue makes large amounts of androgens. or adrenal hyperplasiaEnlarged adrenal glands that make too many hormones., which are most often treated surgically. Given that PMOS affects roughly 10% of the population, she considered our scope to be meaningful and impactful, without needing to broaden into more severe hyperandrogenic conditions.
Integration:
Scope - Her point that targeting PMOS population is a sufficient scope, gave us confidence and expert-backed justification for keeping our project scope focused on PMOS rather than considering expanding into other hyperandrogenic conditions.
Gut-localized approach - Confirming that the gut is a major route for androgen recirculation supports the biological plausibility of our therapeutic and strengthened our decision for a gut-localized approach.
Figure 6. Picture from a meeting with Angelica Lindén Hirschberg
Katia Palombino
Gynecologist and endocrinologist, with a focus on PMOS
Private practice and public hospital work in San Severo, Foggia, Italy
We contacted Katia Palombino to understand how PMOS is seen and treated by clinicians on a daily basis. We asked how common PMOS is and how it is diagnosed and treated. We also asked her about the main concerns and worries expressed by a patient and finally asked her if she would be willing to take part in our survey.
Katia explained that PMOS is common but the term “polycystic ovary” is often overused even among clinicians and specialists. She also said that an ultrasound alone is not enough since ovarian morphology should be judged around 8 years after menarcheA person's first period.. The main criteria are hyperandrogenism, irregular menstrual cycles and polycystic ovaries on ultrasound. She generally avoids giving the contraceptive pill straight away and suggests lifestyle changes with nutrition guidance from a nutritionist and an endocrinologist when needed. She also said that when the cycles become regular due to the contraceptive pill, patients drop the lifestyle changes that matter more. When she does prescribe it, it is most often a pill with an anti-androgenic progestinA synthetic progesterone-like hormone that also blocks the effects of androgens.. She rarely prescribes anti-androgens, such as flutamide, since they require regular check-ups of the liver. She also prescribes inositolA sugar-like compound sold as a supplement and studied for insulin resistance. supplements and metformin in some cases. For most patients, fertility is the main concern. The symptoms usually come back after stopping the pill if the lifestyle has not been corrected.
She said that the microbiome tests are expensive and do not yet give her the results that she can work with. She also mentioned practical barriers, such as the lack of PMOS clinics in her region and the fact that many of her patients cannot afford a nutritionist, a gynecologist, supplements and pills together. For the survey she said that with informed consent and anonymity, the survey should not be a problem.
We were introduced to Lars via last year's iGEM Lund team to explore local collaboration options. Future by Lund is a collaborative platform that drives innovation and development by connecting industry, the public sector, and academia, making them a platform contact rather than a subject-specific expert.
The first meeting (early March) was a general introduction to Future by Lund's platform and offerings (network, venue access, scientific communication support) held before our project topic was finalized. The follow-up meeting (in April) was targeted towards specifying what we actually needed: help organizing an educational event (venue and advertisement), SDG framing, and expert/industry contacts.
Integration:
General Support - As a collaboration partner, their contribution was infrastructure, visibility, and framing support rather than direct project feedback.
Medicon Village is Scandinavia's largest life science park, located in Lund and home to over 180 organizations and 2,800 professionals spanning biotech, pharma, and healthcare. We reached out wanting outreach support, industry contacts, possible lab space, and a clearer picture of how a project like ours could move beyond the iGEM competition.
Future pathway - A first picture of what forming a company around AnTigone would require, and what support is available to do it (LU Innovation, Smile Incubator).
Lab space - Open Lab Skåne as a flexible, pay-per-hour option, not needed for this project, but worth knowing if the work continues.
Simon Ekström
Head of unit: Structural Proteomics
SciLifeLab, Lund University
We met with Simon Ekström and Anton Sellerberg, researchers at SciLifeLab with expertise relevant to protein characterization and structural analysis. We reached out to receive their perspective on how we could characterize and improve our androgen-converting enzyme. They encouraged us to prioritize simple activity assays and protein production, while starting computational modeling in parallel to guide point mutations for improving enzyme performance.
Summary of interview:
Simon Ekström and Anton Sellerberg are researchers at SciLifeLab working with protein structural analysis and mass spectrometry. We reached out to them for advice on how we could experimentally characterize our androgen-converting enzyme and use computational methods to guide its further improvement.
When discussing how to demonstrate enzyme activity, they recommended starting with simpler and faster assays, such as commercial testosterone or estradiolThe main form of estrogen, a female sex hormone. assays, rather than immediately relying on mass spectrometry. Mass spectrometry would be more valuable at a later stage when investigating substrate specificity or identifying reaction products, which would also require appropriate reference compounds.
For improving the enzyme, Anton and Simon recommended starting computational work early and running it in parallel with wet-lab experiments. They suggested using dockingA computer simulation that predicts how well a molecule fits into a protein's binding site. and molecular dynamicsA computer simulation of how the atoms in a molecule move over time. to evaluate enzyme substrate interactions and guide the selection of promising mutations. Rather than introducing several mutations at once, they recommended focusing on point mutations and comparing multiple computational models before selecting candidates for experimental testing.
They also emphasized that producing and characterizing the enzyme should come before more complex experimental systems. When we discussed using microfluidicsHandling tiny amounts of liquid in channels thinner than a hair, for example to mimic body conditions on a chip. to better mimic physiological hormone concentrations, they advised us to postpone this until we had first demonstrated enzymatic conversion in vitro. For protein purification, they considered a His-tagA short string of histidines added to a protein so that it can be purified. suitable and unlikely to significantly interfere with the enzyme's catalytic activity.
Integration:
Experimental priority - Their recommendation to first establish enzyme activity made us prioritize protein expression, purification and straightforward androgen conversion assays before moving to more complex characterization methods.
Computational modeling - Their advice led us to start docking and molecular dynamics alongside our wet lab work, allowing computational results to guide which enzyme variants should be experimentally tested.
Mutation strategy - Their recommendation to focus on point substitutions shaped our protein engineering strategy, where individual mutations could be modeled and compared before selecting promising variants for experimental validation.
Project scope - Their feedback on microfluidics led us to deprioritize complex physiological models and focus our available time and resources on demonstrating enzyme production and androgen conversion first.
Figure 8. Picture from a meeting with Simon Ekström.
Natalie Kazimierczak
Senior Director Business Development
Recipharm Advanced Bio
We spoke with Natalie Kazimierczak and Shubharthi Nandi from Recipharm to introduce AnTigone and scope out whether Recipharm could support us on formulation and eventual scale-upMoving from small laboratory production to large-scale manufacturing.. Natalie walked us through Recipharm's advanced biotherapeutics business: process development, manufacturing, and quality control across their sites and what a potential collaboration path could look like.
Summary of interview:
Recipharm is a global pharmaceutical Contract Development and Manufacturing Organization (CDMO)A company that develops and manufactures medicines for other companies., headquartered in Stockholm and founded in 1995.
We met with Natalie Kazimierczak (Senior Director, Business Development at Recipharm, based in Scotland, working remotely with European customers) and Shubharthi Nandi from the Recipharm team.
Natalie gave background on Recipharm's advanced biotherapeutics business: they cover a range of modalities: RNA and plasmid work, Lipid NanoparticleA tiny fat-based particle used to deliver RNA or other medicines into cells.fill-finishThe last manufacturing step, in which a medicine is filled into vials or capsules and packaged., viral vector manufacturingProducing viruses engineered to deliver genes, for use as medicines., recombinant proteins, and microbial/live biotherapeutics with incoming projects routed to whichever site has the right expertise. Their facilities include process development labs, manufacturing suites at different scales (including microbial fermentation), lyophilizationFreeze-drying. capability at some sites, and in-house quality control, with some specialist testing outsourced to partner laboratories.
In terms of how they typically work with a project, Natalie described starting with smaller-scale process development and proof-of-concept work and then, if a team wants to move further, providing a high-level budget and timeline estimate that could support a funding application (e.g. costs to get to first-in-human clinical material). Her suggested next step was to put a confidentiality agreement in place, have their site teams review whatever information we can share, and set up a deeper technical call with the relevant specialists.
Integration:
Future product development: If we took AnTigone beyond proof of concept, Recipharm would be a valuable first point of contact.
Dimitra Manou
Head of Marketing
Nordic Women's Health Hub
The Nordic Women's Health Hub is an NGO working to advance women's health across the Nordic region, built around four pillars: innovation, knowledge, activism, and partnerships. Dimitra Manou was our first point of contact there.
Summary of interview:
We met with Dimitra Manou, Head of Marketing. This was a preliminary, scoping-style meeting and her role was to assess our project.
On our survey: Her main advice was to pin down our target audience first (patients vs. clinics/hospitals), since GDPR requirements differ depending on which. She seemed interested and asked us to send a plan of what the survey would actually look like (questionnaire, interviews, or focus groups) before taking it further. She confirmed the Hub could potentially help distribute it through their Öresund/Skåne network, but which stakeholders make sense still depends on whether we want patient-level or institutional data.
Magdalena Nour
CEO of Vati of Sweden
Vati of Sweden
Magdalena Nour leads Vati of Sweden, a consultancy that helps organizations integrate the UN SDGs into their strategy and reporting. We contacted her to get insights on our SDG framing and to find practical, low-effort ways to measure and document our sustainability impact. She confirmed our five chosen SDGs were well-suited to our project, and pushed us toward a transparency-first approach, openly naming both the positive and negative impacts of our work rather than aiming for a spotless record.
Magdalena confirmed our five SDGs as a solid selection. She recommended starting with a SWOTStrengths, Weaknesses, Opportunities and Threats: a framework for assessing a project's position. and stakeholder analysis as entry points for structuring our SDG work. On impact measurement, she noted that formal reporting standards (e.g. ISO 26000An international standard giving guidance on social responsibility.) are mainly relevant for compliance purposes (e.g. selling to large companies) and aren't necessary for a project at our scale; impact can instead be quantified from a mix of our own collected data and existing, well-researched data/statistics. On avoiding SDG washing, she pointed out that the goal isn't to have zero negative impact, but to be transparent and conscious about the negative impacts we do have, explaining why they're necessary rather than omitting them. She summarized her overall philosophy as storytelling: transparency and visibly conscious decision-making matter more than a spotless record. She also pointed out that Lund University's position as a top-ranked university in sustainability is an asset we should actively use to frame our project's story.
Integration:
SDG selection - She confirmed our five SDGs (3, 4, 5, 12, 17) fit well, so we kept them unchanged.
Reporting standards - Since formal standards (e.g. ISO 26000) mainly matter for compliance use cases, we skipped them; not worth the cost/effort at our scale.
Impact measurement - We based our impact assessment on our own data plus existing public statistics, rather than a formal framework.
Avoiding SDG washing - We actively built potential negative impacts (current proof-of-concept project and future product) into our SDG analysis, framed around transparency rather than a purely positive picture.
Figure 9. Picture from a meeting with Magdalena Nour.
Shahram Lavasani
Ph.D. in Immunology
CEO of ImmuneBiotech
Dr. Shahram Lavasani was introduced to us by our contact at Medicon, Francesco BezFrancesco BezInnovation Manager
Medicon Village, LundFrancesco has been our constant contact for industry connections, forwarding our outreach to contacts at GutFeelingLabs, ImmuneBiotech,…Go to section, who recognized that our project aligned with his company's research area. Dr. Lavasani's company, ImmuneBiotech, works with precision probiotics to manage various gastrointestinal and neurological conditions (e.g., SIBOSmall intestinal bacterial overgrowth: too many bacteria in the small intestine, which normally holds few., chronic fatigue syndrome, etc.). Dr. Lavasani advised against integrating our construct into a Lactobacillus chassis, recommending instead that we polish our results in E. coli due to time limitations and the difficulty of working with Gram-positiveBacteria with a thick cell wall that stains purple in the Gram test. They are harder to engineer than Gram-negative bacteria such as E. coli. bacteria. He also pointed us to several delayed-release capsule options for probiotic delivery that we could explore in the future.
Summary of interview:
We contacted Dr. Lavasani because of his expertise in probiotics and their use as therapeutic products. We wanted his perspective on possible final chassis selection, probiotic delivery methods and whether probiotic products could potentially cause issues like Small Intestinal Bacterial Overgrowth (SIBO).
When asked about ImmuneBiotech's strategy for selecting their chassis, Dr. Lavasani revealed that they have a functional strain-selection approach, where they select strains by what they produce, and noted a fundamental mismatch with our approach, since we are trying to engineer the chassis to produce what we want. Thus, he was limited in how much direct support they could offer with this.
Nonetheless, Dr. Lavasani shared his experience: when asked about the Lactobacillus, he emphasized that switching to Gram-positive Lactobacillus would be significantly more challenging than continuing with Gram-negative E. coli, especially given our short timeline and lack of prior Gram-positive experience.
When we raised questions about probiotic survival through the GI tract, Dr. Lavasani described delayed-release capsule technologies for probiotic delivery, like Embo caps and Capsugel, that release contents in the small intestine based on time and pH. When asked if there would be a risk of SIBO due to using that, he stated that would not be a concern, since SIBO results from colonic bacteria migrating upward, not from the capsule release.
Integration:
Chassis strategy - we maintained E. coli as our experimental chassis and repositioned chassis migration as theoretical future work requiring no lab validation this year.
Delivery system - we researched possible delayed-release capsule options (Embo caps, Capsugel) for small intestine delivery and pH-resistant coating alternatives.
Nicolas Arriagada
Innovation Developer
LU Innovation, Lund
Nicolas is an innovation developer at LU Innovation, Lund and was our contact person throughout the project. LU Innovation guides students and researchers through the early phases of exploring and verifying an idea. We contacted them to understand what AnTigone could become beyond iGEM and what support exists for taking it further. Based on a first market analysis report, they accepted us into their incubator, where they became our main contact for the entrepreneurial side of the project and remain our most likely route if we continue after the iGEM competition.
Summary of interview:
LU Innovation is Lund University's innovation support organization, which develops ideas and research findings into innovations that solve urgent problems and create value. It guides students and researchers through the early phases of exploring and verifying an idea.
Some of the team wanted to explore whether AnTigone could become a start-up or spin-offA new company created to commercialize a university's research., and needed to know what commercialization would involve and who could support it. We discussed what LU Innovation offers and how the collaboration works, typical project timelines in the incubator, and which funding options we could qualify for. They offer legal support as well. They also introduced us to their programs, for example INSIGHTS, four seminars on exploring an idea's innovative potential, which team members can join to learn the basics of entrepreneurship. One of us has signed up.
To enter the incubator, we first had to produce a market analysis report, which gave us an early picture of the market, competitors, customers, and regulations. It concluded that there is a substantial unmet clinical need and no direct microbial competitor, that our near-term focus should be academic, biotech, and pharma partnerships, and that GMO and EMAThe European Medicines Agency, which evaluates and approves medicines in the EU. regulation are the main hurdles. All further support, including funding, depends on market validation: demonstrated need, customer interest, and contact with companies. A start-up is realistic even with a small core group, as long as at least one or two members commit long term. Whether we continue beyond iGEM will be decided once the competition project is finished.
Integration:
Market analysis - The incubator entry report gave us our first structured view of market, competitors, customers, and regulation.
Entrepreneurship training - Team members were introduced to the program INSIGHTS to learn the basics of turning an idea into a venture.
Future route - The incubator place and free legal advice remain available if we decide to continue after iGEM.
PMOS Surveys
To assess our approach, we developed two surveys and refined them with expert feedback on their legal and clinical aspects.
The clinician survey asked 36 clinicians about current PMOS treatment, their frustrations, and their view of a hypothetical gut-targeted probiotic; 13 responded. The patient survey covered symptoms, treatment experience and openness to a non-hormonal alternative. We did not publish it, because we lacked time to secure the ethical review required for processing health-related personal data.
Clinician Survey
Clinician perspectives on PMOS treatments.
We asked 36 clinicians about current PMOS treatment, their frustrations, and their view of a hypothetical gut-targeted probiotic. 13 responded (36%). Most saw the idea as interesting but wanted more data. Their main concerns were long-term safety, colonization and missing trial data.
Summary:
We wanted to know from people who treat PMOS where current options fall short, and whether a non-hormonal, gut-targeted approach would be clinically useful and not only scientifically interesting.
The survey covered:
Role, patient volume and years of experience.
Current treatments, treatment goals, subtypes and frustrations.
Reaction to a hypothetical daily oral tablet with a genetically engineered bacterium that expresses a 5β-reductase only under gut-like, high-androgen conditions. We asked about initial reaction, place among current treatments, concerns, patient openness, likelihood to prescribe and cost.
We sent the survey by email to clinicians who treat or have treated PMOS. It was sent to at least 5 clinicians at the same time, so a response cannot be traced back to a recipient by its timing. It was available in English, Italian and Spanish (English version below). 13 clinicians completed it. Our note on data policy is at the end.
Open “PMOS Survey for Clinicians (English)” in a new tab ↗A 17-question survey gathering clinical perspectives on current PMOS treatment practices and gauging clinician reaction to a hypothetical gut-targeted probiotic treatment concept.
Figure 12. Clinicians' initial reaction to the hypothetical gut-targeted probiotic (n = 13).Figure 13. Where clinicians would place the probiotic among current treatments (n = 13).Figure 14. Likelihood of prescribing the probiotic if safety and efficacy were shown in clinical trials, from 1 (very unlikely) to 5 (very likely) (n = 13).
Figure 15. Clinicians' primary safety and clinical concerns about the probiotic (n = 13). Multiple answers possible.
Figure 16. Effect of a significantly higher price without insurance or public coverage on clinicians' willingness to recommend the probiotic (n = 13).
In the open questions, respondents asked for clinical evidence: “results from large multicenter RCTsRandomized controlled trials: studies where patients are randomly assigned to treatment or comparison groups.” and “evidence of lowering testosterone levels, both biochemical and clinical.”
Limitations and outlook:
Only 13 of 36 clinicians responded, 11 of them gynecologists, so the results do not cover other specialties, and the 23 who did not respond may think differently. Respondents judged a product that we described ourselves, so their answers reflect our description and not a real product. With so few answers we report counts only and run no statistical tests.
With more time, we would send the survey earlier and to more clinicians, including more endocrinologists and general practitioners, so that we could compare specialties and test differences statistically.
One clinician suggested adding a country-of-practice question. We removed ours on advice, because country, job and patient volume together could identify a clinic.
Patient Survey (not run)
Patient perspectives on living with PMOS.
Survey was not published.
Alongside the clinician survey, we designed a second survey to hear about patients' experience directly: symptom severity and its impact on daily life, treatment experience and satisfaction, gut health symptoms, and openness to a non-hormonal, probiotic-based alternative. It was not published because we lacked time to secure the ethical review required for health-related data from this population.
Summary:
Clinicians can tell us whether our approach is clinically plausible. Only patients can tell us whether it matters to them day to day.
The survey would have covered:
Diagnosis journey, including PMOS phenotype and time to diagnosis.
Symptom severity and its effect on self-esteem, social life, work or study and mental health.
Treatments tried, satisfaction and side effects.
Gut symptoms and prior probiotic use.
Openness to a hypothetical non-hormonal probiotic, including cost and concerns.
The survey was fully written, translated (English, Italian, Spanish, Chinese, and German), and built in SUNET Survey, but no ethical review was ever submitted, and we are not taking it further within this project cycle. See the English version below.
Penning, T. M. (2023). Steroid 5β-reductase (AKR1D1): Purification and characterization. Methods in Enzymology, 689, 277–301. https://doi.org/10.1016/bs.mie.2023.04.012